Scarica l'app Stockscreener
17.08
0.93%
-0.16
Dopo l'orario di chiusura:
17.28
0.20
+1.17%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché TNDM Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$17.24
Aprire:
$17.42
Volume 24 ore:
2.62M
Relative Volume:
1.78
Capitalizzazione di mercato:
$1.49B
Reddito:
$796.00M
Utile/perdita netta:
$-136.49M
Rapporto P/E:
-8.1722
EPS:
-2.09
Flusso di cassa netto:
$-64.24M
1 W Prestazione:
-12.05%
1M Prestazione:
-15.53%
6M Prestazione:
-52.34%
1 anno Prestazione:
-56.37%
Intervallo 1D:
$16.99
$17.73
Intervallo di 1 settimana:
$16.05
$19.52
Portata 52W:
$15.75
$48.24
Tandem Diabetes Care Inc Stock (TNDM) Company Profile
Nome
Tandem Diabetes Care Inc
Settore
Industria
Telefono
858-366-6900
Indirizzo
12400 HIGH BLUFF DRIVE, San Diego, CA
Confronta TNDM con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
TNDM
Tandem Diabetes Care Inc
|
17.08 | 1.49B | 796.00M | -136.49M | -64.24M | -2.09 |
|
ABT
Abbott Laboratories
|
134.11 | 233.36B | 42.34B | 13.50B | 6.66B | 7.71 |
|
BSX
Boston Scientific Corp
|
103.63 | 147.06B | 17.55B | 2.03B | 2.72B | 1.37 |
|
SYK
Stryker Corp
|
391.81 | 145.64B | 23.22B | 2.86B | 3.58B | 7.40 |
|
MDT
Medtronic Plc
|
88.28 | 112.76B | 33.54B | 4.66B | 5.19B | 3.62 |
|
EW
Edwards Lifesciences Corp
|
77.02 | 44.46B | 5.54B | 4.18B | 623.10M | 7.00 |
Tandem Diabetes Care Inc Stock (TNDM) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-06-16 | Iniziato | Truist | Hold |
| 2025-04-10 | Iniziato | Mizuho | Neutral |
| 2025-03-05 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2025-03-04 | Downgrade | Citigroup | Buy → Neutral |
| 2025-03-03 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2025-02-28 | Downgrade | Bernstein | Outperform → Mkt Perform |
| 2024-12-02 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2024-11-06 | Iniziato | Bernstein | Outperform |
| 2024-10-04 | Iniziato | Goldman | Neutral |
| 2024-10-02 | Iniziato | RBC Capital Mkts | Outperform |
| 2024-08-22 | Iniziato | Morgan Stanley | Equal-Weight |
| 2024-08-08 | Iniziato | Canaccord Genuity | Buy |
| 2024-05-30 | Iniziato | Redburn Atlantic | Buy |
| 2024-05-22 | Aggiornamento | Citigroup | Neutral → Buy |
| 2024-04-29 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2024-04-25 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2024-03-26 | Aggiornamento | Stifel | Hold → Buy |
| 2023-08-04 | Downgrade | Citigroup | Buy → Neutral |
| 2023-05-05 | Downgrade | BofA Securities | Neutral → Underperform |
| 2023-04-24 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2023-03-29 | Iniziato | UBS | Neutral |
| 2023-01-26 | Iniziato | Wolfe Research | Peer Perform |
| 2022-11-15 | Aggiornamento | Wells Fargo | Underweight → Equal Weight |
| 2022-10-18 | Iniziato | Barclays | Overweight |
| 2022-10-12 | Iniziato | Jefferies | Buy |
| 2022-08-09 | Downgrade | Wells Fargo | Overweight → Underweight |
| 2022-03-02 | Ripresa | BofA Securities | Neutral |
| 2022-01-19 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2021-07-21 | Ripresa | Cowen | Outperform |
| 2021-05-25 | Iniziato | Barclays | Underweight |
| 2020-12-15 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2020-08-20 | Iniziato | Wells Fargo | Overweight |
| 2020-07-31 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2020-07-06 | Aggiornamento | Citigroup | Neutral → Buy |
| 2020-06-18 | Reiterato | Raymond James | Outperform |
| 2020-04-24 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2020-03-23 | Downgrade | Guggenheim | Buy → Neutral |
| 2020-03-05 | Iniziato | Citigroup | Neutral |
| 2020-02-06 | Iniziato | Raymond James | Outperform |
| 2020-02-04 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2019-10-18 | Iniziato | Guggenheim | Buy |
| 2019-10-04 | Aggiornamento | UBS | Neutral → Buy |
| 2019-05-17 | Reiterato | BofA/Merrill | Neutral |
| 2019-05-13 | Iniziato | SVB Leerink | Outperform |
| 2019-03-08 | Iniziato | BMO Capital Markets | Outperform |
| 2019-03-05 | Reiterato | BofA/Merrill | Neutral |
| 2019-02-27 | Reiterato | Lake Street | Buy |
| 2018-11-21 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2018-09-26 | Reiterato | Dougherty & Company | Buy |
| 2018-09-26 | Reiterato | Piper Jaffray | Overweight |
Mostra tutto
Tandem Diabetes Care Inc Borsa (TNDM) Ultime notizie
Abbott, Tandem Diabetes Care Partner For Glucose-Ketone Sensor for Diabetes Management - MSN
How To Trade (TNDM) - news.stocktradersdaily.com
Digital Diabetes Management Market 2025Growth in Apps, - openPR.com
Novel Diagnostic Technology Disrupting Diabetic Retinopathy Market Generating Billions in Revenue Opportunities - FinancialContent
What Does Tandem Diabetes Care, Inc.'s (NASDAQ:TNDM) Share Price Indicate? - Yahoo Finance
Tandem Diabetes Care’s SWOT analysis: stock faces growth hurdles amid market shifts - Investing.com Nigeria
TNDM: Truist Securities Initiates Coverage with Hold Rating | TN - GuruFocus
TNDM: Truist Securities Initiates Coverage with Hold Rating | TNDM Stock News - GuruFocus
10 Best Stocks to Buy For Beginners Now - Insider Monkey
Truist bullish on diabetes companies citing potential market growth - Seeking Alpha
Truist initiates Tandem Diabetes Care stock with hold rating By Investing.com - Investing.com Canada
Tandem Diabetes (TNDM) Receives Hold Rating from Truist | TNDM S - GuruFocus
Truist Initiates Tandem Diabetes Care at Hold With $24 Price Target - MarketScreener
Abbott Laboratories (NYSE:ABT) Partners With Tandem To Develop Dual Sensor Diabetes Solutions - simplywall.st
Tandem, Abbott team on insulin delivery with glucose-ketone sensor - MedTech Dive
Abbott to pair glucose-ketone sensor with Tandem's insulin pumps - Modern Healthcare
Tandem Diabetes Care Announces Agreement with Abbott for Integration of Automated Insulin Delivery Systems with Future Glucose-Ketone Sensor - MarketScreener
Tandem Diabetes Inks Deal With Abbott For New Diabetes Solutions: Retail Sentiment Stays Subdued By Stocktwits - Investing.com India
Tandem Diabetes Inks Deal With Abbott For New Diabetes Solutions: Retail Sentiment Stays Subdued - Asianet Newsable
Diabetes partnerships abound ahead of ADA - BioWorld MedTech
Tandem Diabetes at Goldman Sachs Conference: Strategic Growth Insights By Investing.com - Investing.com Canada
Transcript : Tandem Diabetes Care, Inc. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-10-2025 08 - MarketScreener
Tandem Diabetes (TNDM) Partners with Abbott for Innovative Diabe - GuruFocus
Tandem, Abbott in deal to combine insulin delivery with glucose-ketone sensor - Seeking Alpha
Tandem Diabetes Care Announces Agreement With Abbott For Integration Of Automated Insulin Delivery Systems With Future Glucose-Ketone Sensor - marketscreener.com
Tandem Diabetes, Abbott to Merge Insulin Pump with Future Glucose-Ketone Sensor - Medical Product Outsourcing
Abbott (ABT) Partners with Tandem Diabetes for Advanced Diabetes Management Solutions | ABT Stock News - GuruFocus
Tandem Diabetes Care Announces Agreement with Abbott for Integration of Automated Insulin Delivery Systems with Future Glucose-Ketone Sensor | TNDM Stock News - GuruFocus
3 Reasons to Sell TNDM and 1 Stock to Buy Instead - Yahoo Finance
Transcript : Tandem Diabetes Care, Inc. Presents at Jefferies Global Healthcare Conference 2025, Jun-04-2025 03 - MarketScreener
Tandem to pay Roche $36M in patent dispute settlement - MSN
Tandem Diabetes Care: A Barbell Bet On A High-Stakes Turnaround (NASDAQ:TNDM) - Seeking Alpha
(TNDM) Long Term Investment Analysis - news.stocktradersdaily.com
Tandem Diabetes at Jefferies: Expanding Market Horizons By Investing.com - Investing.com Canada
How the Non-Invasive Drug Delivery Device Market Will Evolve - openPR.com
Do You Believe in the Long-Term Growth Potential of Tandem Diabetes Care (TNDM)? - Insider Monkey
Roche settles UPC dispute over insulin distribution technology - JUVE Patent
Goldman Sachs Bullish On Dexcom And Insulet As Diabetes Tech Surges - Benzinga
Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Receives Average Recommendation of “Hold” from Analysts - Defense World
Tandem Diabetes Care Inc (TNDM) Shares Gap Down to $20.62 on May 30 - GuruFocus
Tandem Diabetes Care (TNDM) Up 6.5% Since Last Earnings Report: Can It Continue? - Yahoo Finance
Contrasting Tandem Diabetes Care (NASDAQ:TNDM) and PolyPid (NASDAQ:PYPD) - Defense World
Cetera Investment Advisers Acquires 981 Shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM) - Defense World
Reflecting On Healthcare Technology Stocks’ Q1 Earnings: Tandem Diabetes (NASDAQ:TNDM) - Yahoo Finance
Tandem Diabetes and Roche Reach a Patent Settlement - MSN
How the (TNDM) price action is used to our Advantage - news.stocktradersdaily.com
Tandem Diabetes, Roche enter patent settlement agreement - Yahoo Finance
Tandem Diabetes Care (TNDM) Settles Patent Dispute with Roche - GuruFocus
Should Tandem Diabetes Stock Stay in Your Portfolio Now? - MSN
Tandem Diabetes Care Inc Azioni (TNDM) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Tandem Diabetes Care Inc Azioni (TNDM) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Novara Mark David | EVP & CHIEF COMMERCIAL OFFICER |
Jun 16 '25 |
Option Exercise |
0.00 |
7,414 |
0 |
32,609 |
| Cha Myoungil | Director |
Jun 16 '25 |
Option Exercise |
0.00 |
1,749 |
0 |
13,699 |
| Malagueira Joao Paulo Falcao | Director |
Jun 16 '25 |
Option Exercise |
0.00 |
1,749 |
0 |
13,699 |
| Sodhi Rajwant | Director |
May 22 '25 |
Option Exercise |
20.64 |
4,387 |
90,548 |
15,521 |
| McGroddy-Goetz Kathleen | Director |
May 22 '25 |
Option Exercise |
20.64 |
4,387 |
90,548 |
17,853 |
| Cha Myoungil | Director |
May 22 '25 |
Option Exercise |
20.64 |
4,387 |
90,548 |
11,950 |
| ROBERTSON REBECCA B | Director |
May 22 '25 |
Option Exercise |
20.64 |
4,387 |
90,548 |
13,783 |
| Howell Peyton R | Director |
May 22 '25 |
Option Exercise |
20.64 |
4,387 |
90,548 |
21,077 |
| TWOMEY CHRISTOPHER J | Director |
May 22 '25 |
Option Exercise |
20.64 |
4,387 |
90,548 |
15,675 |
| Malagueira Joao Paulo Falcao | Director |
May 22 '25 |
Option Exercise |
20.64 |
4,387 |
90,548 |
11,950 |
0.54%
1.82%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):